| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultrasonography | 76 | 2022 | 381 | 14.980 |
Why?
|
| Carpal Tunnel Syndrome | 20 | 2022 | 61 | 6.630 |
Why?
|
| Peripheral Nerves | 14 | 2022 | 63 | 5.410 |
Why?
|
| Muscle, Skeletal | 19 | 2020 | 537 | 4.270 |
Why?
|
| Amyotrophic Lateral Sclerosis | 12 | 2020 | 61 | 3.750 |
Why?
|
| Neural Conduction | 24 | 2021 | 89 | 3.680 |
Why?
|
| Median Nerve | 15 | 2022 | 49 | 3.580 |
Why?
|
| Ulnar Neuropathies | 5 | 2021 | 17 | 2.550 |
Why?
|
| Neuromuscular Junction | 6 | 2022 | 66 | 2.520 |
Why?
|
| Ulnar Nerve | 10 | 2022 | 23 | 2.440 |
Why?
|
| Peripheral Nervous System Diseases | 6 | 2022 | 51 | 2.380 |
Why?
|
| Humans | 114 | 2022 | 32968 | 2.330 |
Why?
|
| Electrodiagnosis | 11 | 2022 | 41 | 2.310 |
Why?
|
| Neuromuscular Diseases | 7 | 2021 | 15 | 1.990 |
Why?
|
| Male | 68 | 2022 | 19754 | 1.780 |
Why?
|
| Occupational Diseases | 6 | 2016 | 78 | 1.760 |
Why?
|
| Polyneuropathies | 5 | 2019 | 11 | 1.660 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 3 | 2021 | 6 | 1.650 |
Why?
|
| Muscular Atrophy, Spinal | 3 | 2022 | 4 | 1.520 |
Why?
|
| Adult | 47 | 2022 | 9586 | 1.520 |
Why?
|
| Female | 61 | 2022 | 20375 | 1.470 |
Why?
|
| Diaphragm | 7 | 2018 | 38 | 1.440 |
Why?
|
| Middle Aged | 48 | 2020 | 12203 | 1.440 |
Why?
|
| Oligonucleotides | 3 | 2022 | 30 | 1.360 |
Why?
|
| Myositis, Inclusion Body | 3 | 2019 | 7 | 1.240 |
Why?
|
| Aged | 34 | 2020 | 10637 | 1.010 |
Why?
|
| Charcot-Marie-Tooth Disease | 2 | 2020 | 8 | 0.940 |
Why?
|
| Brachial Plexus | 2 | 2018 | 26 | 0.940 |
Why?
|
| Radial Nerve | 4 | 2022 | 17 | 0.940 |
Why?
|
| Sural Nerve | 4 | 2020 | 27 | 0.920 |
Why?
|
| Cubital Tunnel Syndrome | 4 | 2008 | 10 | 0.900 |
Why?
|
| Azo Compounds | 2 | 2021 | 4 | 0.880 |
Why?
|
| Nerve Compression Syndromes | 3 | 2013 | 9 | 0.860 |
Why?
|
| Hispanic Americans | 7 | 2016 | 930 | 0.860 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2021 | 106 | 0.850 |
Why?
|
| Elbow | 6 | 2021 | 29 | 0.850 |
Why?
|
| Pyrimidines | 2 | 2021 | 62 | 0.840 |
Why?
|
| Young Adult | 13 | 2020 | 2738 | 0.820 |
Why?
|
| Neuromuscular Agents | 2 | 2021 | 29 | 0.810 |
Why?
|
| Biological Products | 2 | 2021 | 77 | 0.790 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2022 | 2 | 0.780 |
Why?
|
| Brachial Plexus Neuritis | 1 | 2022 | 1 | 0.760 |
Why?
|
| Electromyography | 8 | 2019 | 60 | 0.760 |
Why?
|
| Elbow Joint | 2 | 2021 | 66 | 0.750 |
Why?
|
| Motor Neuron Disease | 2 | 2019 | 3 | 0.750 |
Why?
|
| Wrist | 4 | 2020 | 48 | 0.750 |
Why?
|
| Forearm | 4 | 2020 | 46 | 0.720 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 770 | 0.710 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2021 | 3 | 0.700 |
Why?
|
| Stroke | 6 | 2013 | 610 | 0.700 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2021 | 9 | 0.700 |
Why?
|
| Observer Variation | 3 | 2019 | 96 | 0.700 |
Why?
|
| Myasthenia Gravis | 2 | 2016 | 15 | 0.690 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 29 | 0.690 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2017 | 79 | 0.690 |
Why?
|
| Myotonic Disorders | 1 | 2020 | 3 | 0.650 |
Why?
|
| Radial Neuropathy | 2 | 2011 | 11 | 0.650 |
Why?
|
| Child | 8 | 2022 | 2478 | 0.640 |
Why?
|
| Hand | 1 | 2020 | 73 | 0.630 |
Why?
|
| Curriculum | 3 | 2019 | 211 | 0.630 |
Why?
|
| Motor Neurons | 1 | 2020 | 40 | 0.630 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 32 | 0.620 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2019 | 6 | 0.610 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 105 | 0.600 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 2019 | 1 | 0.600 |
Why?
|
| Tracheostomy | 1 | 2019 | 28 | 0.580 |
Why?
|
| Vagus Nerve | 2 | 2017 | 30 | 0.580 |
Why?
|
| Nerve Tissue | 1 | 2018 | 2 | 0.580 |
Why?
|
| Body Height | 1 | 2018 | 33 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 1310 | 0.580 |
Why?
|
| Body Weight | 2 | 2018 | 302 | 0.570 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.570 |
Why?
|
| Fasciitis | 1 | 2018 | 2 | 0.570 |
Why?
|
| Musculoskeletal Diseases | 2 | 2016 | 42 | 0.570 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2018 | 6 | 0.560 |
Why?
|
| Eosinophilia | 1 | 2018 | 11 | 0.560 |
Why?
|
| Pilot Projects | 7 | 2020 | 566 | 0.560 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2018 | 36 | 0.550 |
Why?
|
| Reference Values | 5 | 2022 | 238 | 0.540 |
Why?
|
| Case-Control Studies | 9 | 2020 | 880 | 0.540 |
Why?
|
| Upper Extremity | 1 | 2017 | 59 | 0.520 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 4 | 0.520 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 241 | 0.520 |
Why?
|
| Food-Processing Industry | 3 | 2014 | 37 | 0.520 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2017 | 12 | 0.510 |
Why?
|
| Nutritional Sciences | 1 | 2017 | 9 | 0.510 |
Why?
|
| Peroneal Nerve | 2 | 2013 | 15 | 0.510 |
Why?
|
| Scapula | 1 | 2017 | 20 | 0.510 |
Why?
|
| Aged, 80 and over | 12 | 2018 | 4065 | 0.500 |
Why?
|
| Adolescent | 9 | 2020 | 3643 | 0.500 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 18 | 0.480 |
Why?
|
| Receptors, Cholinergic | 1 | 2016 | 22 | 0.480 |
Why?
|
| Diabetic Neuropathies | 2 | 2017 | 26 | 0.480 |
Why?
|
| Muscle Cramp | 1 | 2015 | 3 | 0.470 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2015 | 4 | 0.470 |
Why?
|
| Bell Palsy | 1 | 2015 | 2 | 0.460 |
Why?
|
| Facial Muscles | 1 | 2015 | 2 | 0.460 |
Why?
|
| Clinical Competence | 3 | 2022 | 338 | 0.460 |
Why?
|
| Facial Nerve | 1 | 2015 | 4 | 0.460 |
Why?
|
| Biomedical Research | 1 | 2017 | 172 | 0.460 |
Why?
|
| Lymphoma | 1 | 2015 | 33 | 0.450 |
Why?
|
| Sports | 1 | 2015 | 41 | 0.430 |
Why?
|
| Brain Concussion | 1 | 2015 | 65 | 0.430 |
Why?
|
| Prospective Studies | 7 | 2021 | 2338 | 0.430 |
Why?
|
| Meningitis | 1 | 2014 | 9 | 0.430 |
Why?
|
| Carpal Bones | 1 | 2014 | 16 | 0.430 |
Why?
|
| Retrospective Studies | 8 | 2022 | 3708 | 0.420 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 883 | 0.410 |
Why?
|
| Ganglion Cysts | 1 | 2013 | 6 | 0.410 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2013 | 5 | 0.390 |
Why?
|
| Peripheral Nervous System | 2 | 2014 | 5 | 0.390 |
Why?
|
| Sciatic Nerve | 1 | 2013 | 36 | 0.390 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 80 | 0.390 |
Why?
|
| Nervous System | 1 | 2013 | 13 | 0.390 |
Why?
|
| Disease Management | 1 | 2013 | 128 | 0.380 |
Why?
|
| Age Factors | 2 | 2013 | 1202 | 0.370 |
Why?
|
| African Americans | 1 | 2019 | 1425 | 0.370 |
Why?
|
| Poultry Products | 1 | 2012 | 13 | 0.360 |
Why?
|
| Emigrants and Immigrants | 3 | 2016 | 240 | 0.360 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 1581 | 0.360 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3460 | 0.360 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 59 | 0.360 |
Why?
|
| Joint Instability | 1 | 2013 | 86 | 0.350 |
Why?
|
| Mononeuropathies | 1 | 2011 | 2 | 0.350 |
Why?
|
| Posture | 2 | 2015 | 56 | 0.350 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2009 | 22 | 0.340 |
Why?
|
| Steroids | 1 | 2011 | 34 | 0.340 |
Why?
|
| Myography | 3 | 2018 | 6 | 0.340 |
Why?
|
| Infant | 3 | 2021 | 1083 | 0.340 |
Why?
|
| Electric Impedance | 3 | 2018 | 13 | 0.340 |
Why?
|
| Median Neuropathy | 2 | 2013 | 7 | 0.340 |
Why?
|
| Arm Injuries | 1 | 2011 | 22 | 0.340 |
Why?
|
| Mass Screening | 1 | 2013 | 268 | 0.330 |
Why?
|
| Wounds, Gunshot | 1 | 2011 | 34 | 0.330 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2010 | 8 | 0.330 |
Why?
|
| Brachial Artery | 2 | 2013 | 70 | 0.330 |
Why?
|
| Deglutition Disorders | 1 | 2010 | 52 | 0.310 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 576 | 0.310 |
Why?
|
| Cranial Nerves | 1 | 2009 | 7 | 0.310 |
Why?
|
| Incontinentia Pigmenti | 1 | 2009 | 1 | 0.300 |
Why?
|
| Thromboembolism | 1 | 2009 | 38 | 0.290 |
Why?
|
| Edema | 1 | 2008 | 27 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2022 | 412 | 0.290 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 52 | 0.270 |
Why?
|
| Anatomy, Cross-Sectional | 5 | 2013 | 15 | 0.270 |
Why?
|
| Muscle Contraction | 2 | 2020 | 113 | 0.260 |
Why?
|
| Students, Medical | 2 | 2020 | 132 | 0.260 |
Why?
|
| Tibial Nerve | 2 | 2020 | 21 | 0.260 |
Why?
|
| Joints | 1 | 2006 | 12 | 0.250 |
Why?
|
| Arteries | 1 | 2006 | 71 | 0.240 |
Why?
|
| Aneurysm, False | 1 | 2005 | 14 | 0.230 |
Why?
|
| Telencephalon | 1 | 2005 | 3 | 0.230 |
Why?
|
| Nervous System Malformations | 1 | 2005 | 9 | 0.230 |
Why?
|
| Tuberous Sclerosis | 1 | 2005 | 8 | 0.230 |
Why?
|
| Spinal Puncture | 1 | 2005 | 20 | 0.230 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2005 | 41 | 0.230 |
Why?
|
| Epinephrine | 1 | 2005 | 42 | 0.230 |
Why?
|
| Quadriceps Muscle | 2 | 2015 | 33 | 0.230 |
Why?
|
| Medical Staff, Hospital | 1 | 2005 | 21 | 0.220 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 28 | 0.220 |
Why?
|
| Intensive Care Units | 3 | 2015 | 115 | 0.220 |
Why?
|
| Dysarthria | 1 | 2004 | 3 | 0.220 |
Why?
|
| Cerebral Hemorrhage | 1 | 2005 | 70 | 0.220 |
Why?
|
| Prevalence | 5 | 2016 | 1002 | 0.220 |
Why?
|
| Heptanoic Acids | 1 | 2004 | 26 | 0.220 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 487 | 0.220 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 245 | 0.220 |
Why?
|
| Respiratory Paralysis | 2 | 2015 | 3 | 0.210 |
Why?
|
| Pyrroles | 1 | 2004 | 52 | 0.210 |
Why?
|
| Back Pain | 2 | 2014 | 29 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Disease Progression | 4 | 2019 | 594 | 0.200 |
Why?
|
| United States | 4 | 2020 | 4132 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 527 | 0.200 |
Why?
|
| Child, Preschool | 2 | 2020 | 1282 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Hypertrophy | 1 | 2022 | 30 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 149 | 0.190 |
Why?
|
| Logistic Models | 2 | 2016 | 783 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Shoulder Pain | 1 | 2022 | 10 | 0.190 |
Why?
|
| Organ Size | 2 | 2013 | 220 | 0.190 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 47 | 0.190 |
Why?
|
| Neurologic Examination | 3 | 2017 | 28 | 0.190 |
Why?
|
| Muscle Weakness | 3 | 2017 | 36 | 0.180 |
Why?
|
| Time Factors | 4 | 2019 | 2195 | 0.180 |
Why?
|
| Vital Capacity | 2 | 2018 | 42 | 0.180 |
Why?
|
| Learning | 1 | 2022 | 80 | 0.180 |
Why?
|
| Consensus | 1 | 2022 | 87 | 0.180 |
Why?
|
| Education, Distance | 1 | 2021 | 18 | 0.170 |
Why?
|
| North Carolina | 5 | 2016 | 1550 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2287 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2022 | 251 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 6 | 0.170 |
Why?
|
| Evoked Potentials, Motor | 2 | 2018 | 8 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 13 | 0.170 |
Why?
|
| HIV | 1 | 2020 | 25 | 0.170 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 30 | 0.160 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 290 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2019 | 1852 | 0.160 |
Why?
|
| Mutation | 1 | 2022 | 499 | 0.160 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 894 | 0.160 |
Why?
|
| Fluoroscopy | 1 | 2020 | 39 | 0.160 |
Why?
|
| Cadaver | 2 | 2013 | 165 | 0.160 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 780 | 0.160 |
Why?
|
| Neurology | 1 | 2020 | 48 | 0.160 |
Why?
|
| Injections, Spinal | 1 | 2020 | 108 | 0.160 |
Why?
|
| Movement Disorders | 2 | 2010 | 26 | 0.160 |
Why?
|
| Taxoids | 1 | 2020 | 55 | 0.160 |
Why?
|
| Demyelinating Diseases | 1 | 2019 | 9 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 563 | 0.160 |
Why?
|
| Monocytes | 1 | 2020 | 132 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 49 | 0.150 |
Why?
|
| Lipids | 1 | 2020 | 230 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 34 | 0.150 |
Why?
|
| Anisotropy | 1 | 2019 | 12 | 0.150 |
Why?
|
| Macrophages | 1 | 2020 | 195 | 0.150 |
Why?
|
| Myotonic Dystrophy | 1 | 2018 | 5 | 0.150 |
Why?
|
| Survival Rate | 2 | 2019 | 895 | 0.140 |
Why?
|
| Sample Size | 1 | 2018 | 39 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2019 | 241 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 194 | 0.140 |
Why?
|
| Immunosuppression | 1 | 2018 | 120 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2018 | 48 | 0.140 |
Why?
|
| Eosinophils | 1 | 2018 | 29 | 0.140 |
Why?
|
| Muscular Diseases | 2 | 2011 | 23 | 0.140 |
Why?
|
| Prednisone | 1 | 2018 | 63 | 0.140 |
Why?
|
| Animals | 4 | 2021 | 7599 | 0.140 |
Why?
|
| Critical Illness | 2 | 2015 | 84 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 308 | 0.130 |
Why?
|
| Equipment Design | 1 | 2018 | 179 | 0.130 |
Why?
|
| Vaccination | 1 | 2018 | 146 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 101 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 308 | 0.130 |
Why?
|
| Incidence | 2 | 2013 | 1246 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 42 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 541 | 0.120 |
Why?
|
| Health Status | 1 | 2018 | 403 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2018 | 219 | 0.120 |
Why?
|
| Atrophy | 1 | 2016 | 46 | 0.120 |
Why?
|
| Community Health Planning | 1 | 2016 | 8 | 0.120 |
Why?
|
| Action Potentials | 1 | 2016 | 186 | 0.120 |
Why?
|
| HIV Infections | 1 | 2020 | 424 | 0.110 |
Why?
|
| Wasting Syndrome | 1 | 2015 | 14 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 265 | 0.110 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2015 | 49 | 0.110 |
Why?
|
| Hyoid Bone | 1 | 2015 | 5 | 0.110 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 42 | 0.110 |
Why?
|
| Disulfiram | 1 | 2014 | 1 | 0.110 |
Why?
|
| Alcohol Deterrents | 1 | 2014 | 2 | 0.110 |
Why?
|
| Laryngeal Muscles | 1 | 2015 | 17 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 599 | 0.110 |
Why?
|
| Deglutition | 1 | 2015 | 30 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 18 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2009 | 694 | 0.110 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1163 | 0.110 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2014 | 4 | 0.110 |
Why?
|
| Ideal Body Weight | 1 | 2014 | 7 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2020 | 801 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 112 | 0.110 |
Why?
|
| Muscle Strength | 1 | 2015 | 159 | 0.110 |
Why?
|
| Workplace | 1 | 2014 | 50 | 0.110 |
Why?
|
| Child Care | 1 | 2014 | 12 | 0.100 |
Why?
|
| Industry | 1 | 2014 | 15 | 0.100 |
Why?
|
| Tennis Elbow | 1 | 2014 | 18 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 754 | 0.100 |
Why?
|
| Alcoholism | 1 | 2014 | 102 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2014 | 108 | 0.100 |
Why?
|
| Intercostal Muscles | 1 | 2013 | 1 | 0.100 |
Why?
|
| Respiratory Muscles | 1 | 2013 | 5 | 0.100 |
Why?
|
| Athletes | 1 | 2013 | 73 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 100 | 0.100 |
Why?
|
| Comorbidity | 2 | 2011 | 573 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2016 | 909 | 0.090 |
Why?
|
| Echocardiography | 1 | 2013 | 191 | 0.090 |
Why?
|
| Life Style | 1 | 2013 | 409 | 0.090 |
Why?
|
| Wrist Joint | 1 | 2011 | 60 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 215 | 0.080 |
Why?
|
| Depression | 1 | 2014 | 448 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2011 | 61 | 0.080 |
Why?
|
| Muscular Atrophy | 1 | 2011 | 76 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2011 | 73 | 0.080 |
Why?
|
| Neurophysiology | 1 | 2010 | 10 | 0.080 |
Why?
|
| Pseudobulbar Palsy | 1 | 2010 | 5 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 20 | 0.080 |
Why?
|
| Mood Disorders | 1 | 2010 | 21 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 950 | 0.080 |
Why?
|
| Endoscopy | 1 | 2010 | 56 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 91 | 0.080 |
Why?
|
| Vasculitis | 1 | 2009 | 24 | 0.080 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 19 | 0.080 |
Why?
|
| Risk Factors | 2 | 2009 | 4001 | 0.080 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 49 | 0.080 |
Why?
|
| Myelin P0 Protein | 1 | 2009 | 4 | 0.080 |
Why?
|
| Family Health | 1 | 2009 | 78 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2009 | 148 | 0.070 |
Why?
|
| Causality | 1 | 2008 | 39 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1477 | 0.070 |
Why?
|
| Aspirin | 1 | 2009 | 62 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 85 | 0.070 |
Why?
|
| Physicians | 1 | 2010 | 165 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 282 | 0.070 |
Why?
|
| Asthma | 1 | 2010 | 262 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 467 | 0.070 |
Why?
|
| Denervation | 1 | 2007 | 12 | 0.070 |
Why?
|
| Electric Stimulation | 1 | 2007 | 106 | 0.070 |
Why?
|
| Reaction Time | 1 | 2007 | 119 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 11 | 0.060 |
Why?
|
| Torsion Abnormality | 1 | 2006 | 6 | 0.060 |
Why?
|
| Weight Loss | 1 | 2010 | 462 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 104 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2007 | 174 | 0.060 |
Why?
|
| Paresthesia | 1 | 2005 | 9 | 0.060 |
Why?
|
| Tissue Adhesions | 1 | 2005 | 12 | 0.060 |
Why?
|
| Angiomyolipoma | 1 | 2005 | 6 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 97 | 0.060 |
Why?
|
| Rhabdomyoma | 1 | 2005 | 3 | 0.060 |
Why?
|
| Choristoma | 1 | 2005 | 14 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2005 | 39 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 57 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2005 | 54 | 0.060 |
Why?
|
| Thalamus | 1 | 2005 | 33 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 19 | 0.060 |
Why?
|
| Pyridostigmine Bromide | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lovastatin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Th2 Cells | 1 | 2004 | 9 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2005 | 56 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2004 | 6 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2005 | 20 | 0.060 |
Why?
|
| Pravastatin | 1 | 2004 | 13 | 0.060 |
Why?
|
| Skull | 1 | 2005 | 48 | 0.060 |
Why?
|
| Simvastatin | 1 | 2004 | 24 | 0.060 |
Why?
|
| Dogs | 2 | 2015 | 120 | 0.050 |
Why?
|
| Quality of Life | 1 | 2010 | 976 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 58 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2004 | 119 | 0.050 |
Why?
|
| Cytokines | 1 | 2004 | 247 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2005 | 205 | 0.050 |
Why?
|
| Mitochondria | 1 | 2004 | 214 | 0.050 |
Why?
|
| Prognosis | 1 | 2006 | 1547 | 0.050 |
Why?
|
| Educational Status | 1 | 2022 | 183 | 0.050 |
Why?
|
| Brain | 1 | 2009 | 949 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 11 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1152 | 0.040 |
Why?
|
| Obesity | 1 | 2008 | 1179 | 0.040 |
Why?
|
| Professional Practice | 1 | 2020 | 24 | 0.040 |
Why?
|
| Career Choice | 1 | 2020 | 44 | 0.040 |
Why?
|
| Research | 1 | 2020 | 76 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2005 | 828 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 31 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 44 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 36 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 65 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 43 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 99 | 0.030 |
Why?
|
| Hypertension | 1 | 2004 | 983 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 15 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2020 | 325 | 0.030 |
Why?
|
| Head | 1 | 2017 | 56 | 0.030 |
Why?
|
| Critical Care | 1 | 2015 | 109 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2015 | 205 | 0.030 |
Why?
|
| Food Industry | 1 | 2013 | 9 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2014 | 205 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2015 | 432 | 0.020 |
Why?
|
| Leprosy, Lepromatous | 1 | 2011 | 1 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1015 | 0.020 |
Why?
|
| Adiposity | 1 | 2011 | 199 | 0.020 |
Why?
|
| Emaciation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 53 | 0.020 |
Why?
|
| Essential Tremor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 74 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2010 | 77 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 200 | 0.020 |
Why?
|
| Weight Gain | 1 | 2010 | 112 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2010 | 89 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 363 | 0.020 |
Why?
|